“We’re building a strong scientific base for KSM-66 as a clinically-tested adaptogen,” said Ixoreal Biomed director Kartikeya Baldwa.
Ixoreal Biomed (Hyderabad, India) plans to increase North American demand for ashwagandha (Withania somnifera) by increasing the supporting science behind its KSM-66 advanced-form ashwagandha.
Acknowledging that the North American ashwagandha market is “largely undeveloped,” Ixoreal Biomed says it is starting to publish its studies on KSM-66 on human health factors including energy, infertility, immunity, and longevity. The first of five studies Ixoreal Biomed has conducted is now published in the Indian Journal of Psychiatry. It is a human clinical trial on 64 adults under stress conditions.
“We’re building a strong scientific base for KSM-66 as a clinically-tested adaptogen,” said Ixoreal Biomed director Kartikeya Baldwa. “Even though this application had been known through traditional use, very few studies had been conducted prior to our work with KSM-66. We’ve committed our company to be the leader in ashwagandha scientific data.”
KSM-66 is a GRAS-affirmed and Halal-certified ashwagandha ingredient.
The Nutritional Outlook Podcast Episode 33: Keeping up with contract manufacturing
July 26th 2024Nutritional Outlook talks to Lauren Samot, commercial innovation leader, and Blayney McEneaney, sales executive at Vitaquest International, about trends within the contract manufacturing space, and the ways in which contract manufacturers like Vitaquest keep up with the market and differentiate themselves from the competition.